Treatment of cognitive impairment in HIV-infected patients receiving tuberculosis therapy: results of an observational program
Notice bibliographique
Résumé
Objective. To obtain data on the efficacy and safety of Prospekta in the therapy of cognitive impairment (CI) in HIV-infected patients with chemotherapy for tuberculosis. Patients and methods. A total of 120 patients older than 18 years (mean age 43.9 years) who met the inclusion criteria were included in the observational program. All participants were assessed initially, after 4, 8, 12, 24 weeks using the Montreal Cognitive Assessment Scale (MoCA), and quality of life using the European Quality of Life Questionnaire. Patients were randomized into two groups: the group of starting administration of Prospekta (n = 60) – patients received Prospect for 12 weeks against the background of tuberculosis chemotherapy, the group of delayed administration of Prospekta (n = 60) – patients received tuberculosis chemotherapy for 12 weeks without Prospekta. After 12 weeks, the therapy was changed: patients in the initial prescription group continued TB chemotherapy for another 12 weeks without Prospecta. Patients in the delayed prescription group were treated with Prospecta for 12 weeks against the background of chemotherapy. Patients were ranked into three subgroups depending on the severity of CI: subjective CI (SubCI; n = 8), moderate CI (MCI; n = 59), severe CI (SCI; n = 53). Patients' demographic characteristics were comparable across groups/subgroups. Results. Patients with SubCI in the Prospekta starter group showed an increase in mean MoCA score from 27.1 ± 1.3 to 29.1 ± 0.9 by 12 weeks of therapy (vs. 26.0 to 27.0 in the delayed group, p = 1.0000); after changing therapy with Prospekta exclusion at visit 4, there was a change in mean MoCA score of -0.1 by 24 weeks of therapy (vs. 2.0 on Prospekta addition, p = 1.0000). Patients with MCI in the Prospekta starter group showed an increase in mean MoCA score by 12 weeks of therapy from 22.2 ± 2.0 to 25.7 ± 2.3 (vs. 20.0 ± 1.2 to 20.9 ± 2.6 points in the delayed prescription group, p ≤ 0.0001), after changing the therapy with Prospekta exclusion at visit 4, there was a 0.1 change in the mean MoCA score by 24 weeks of treatment (vs. 3.4 points on Prospekta addition, p ≤ 0.0001). Patients with SCI in the Prospekta starter group showed an increase in mean MoCA score by 12 weeks of therapy from 15.8 ± 2.5 to 22.3 ± 3.8 (vs. 16.3 ± 1.7 to 18.7 ± 2.5 points in the delayed prescription group, p = 0.0063), after the change of therapy with Prospekta exclusion at visit 4, there was a 0.8 change in the mean MoCA score by 24 weeks of treatment (vs. 4.0 points on Prospekta addition, p ≤ 0.0001). Patients in the Prospekta starter group showed a 10-fold advantage in quality of life after 4 weeks compared to respondents in the delayed prescription group. A total of 9 AEs were recorded in 4 patients, among which 8 AEs were mild and 1 AE was severe. All of them were unrelated to the drug. Conclusion. The efficacy and safety of Prospekta in the treatment of SubCI, MCI and SCI in HIV-associated patients receiving tuberculosis chemotherapy have been demonstrated. Key words: cognitive disorders of varying severity, pulmonary tuberculosis, HIV infection, Prospekta, chemotherapy
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,003 | 0,005 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,001 |
| Bibliométrie | 0,001 | 0,001 |
| Études des sciences et des technologies | 0,001 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,001 |
| Intégrité de la recherche | 0,000 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,001 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».